Group 1 - The company held its fourth supervisory board meeting, with all three supervisors present, confirming compliance with relevant laws and regulations [1][2] - The supervisory board approved the proposal to temporarily use part of the idle raised funds to supplement working capital, which is expected to enhance fund utilization efficiency and reduce financial costs [1][2] - The decision to use idle funds does not affect the normal implementation of investment projects and is in the interest of the company and all shareholders [1]

Group 1 - The company received a resignation letter from supervisor Li Liang due to personal reasons, which will lead to the supervisory board having fewer members than the legal minimum [1] - The company plans to abolish the supervisory board, and Li Liang will continue to fulfill his duties until the abolition takes effect [1] - The company expressed gratitude for Li Liang's contributions during his tenure as a supervisor [1] Group 2 - The company approved the temporary use of up to RMB 100 million of idle raised funds to supplement working capital, with a usage period not exceeding 12 months [2] - The company has actually used RMB 100 million of idle raised funds for temporary working capital [3] - As of July 8, 2025, the company has fully repaid the RMB 100 million of idle raised funds to the special account for raised funds [4]

Core Viewpoint - The company, Shengmei Semiconductor Equipment (Shanghai) Co., Ltd., is undergoing significant governance changes, including the cancellation of the supervisory board and an increase in the number of directors, which may impact its operational structure and strategic direction [2][7]. Group 1: Stock Performance - As of June 27, 2025, Shengmei Shanghai's stock closed at 112.9 yuan, reflecting a 3.11% increase from the previous week [1]. - The stock reached a peak price of 115.5 yuan and a low of 108.45 yuan during the week [1]. - The company's current total market capitalization is 49.822 billion yuan, ranking 16th out of 161 in the semiconductor sector and 273rd out of 5,151 in the A-share market [1]. Group 2: Corporate Governance Changes - The second supervisory board's twentieth meeting approved three key resolutions: the cancellation of the supervisory board, an increase in the number of directors, and adjustments to the share repurchase price limit [2]. - The company plans to hold its third extraordinary general meeting on July 15, 2025, to discuss the cancellation of the supervisory board and the increase in the number of directors [3]. - The board intends to increase its size from 6 to 8 members, adding independent director Jiang Shoule [5]. Group 3: Financial Management - The company approved the temporary use of up to 250 million yuan of idle raised funds to supplement working capital, with a validity period of 12 months from the board's approval [6][7]. - The share repurchase price limit has been adjusted from 99.02 yuan per share to 120.00 yuan per share to ensure the smooth implementation of the repurchase plan [8].

Core Viewpoint - The company, Sely Medical, has experienced a significant increase in stock price and has made announcements regarding the use of idle funds and credit rating adjustments [1][2][3]. Group 1: Stock Performance - As of June 27, 2025, Sely Medical's stock closed at 13.91 yuan, up 14.49% from the previous week [1]. - The stock reached a peak price of 14.2 yuan and a low of 11.65 yuan during the week [1]. - The company's current total market capitalization is 2.657 billion yuan, ranking 30th in the pharmaceutical commercial sector and 4521st in the A-share market [1]. Group 2: Company Announcements - Sely Medical plans to use up to 32.5 million yuan of idle raised funds to temporarily supplement working capital, with a usage period not exceeding 12 months [2]. - As of May 31, 2025, the company had utilized 201.8791 million yuan of the 2020 convertible bond funds, achieving an overall investment progress of 37.90% [2]. - The board and supervisory committee approved the use of idle funds, stating it would enhance fund efficiency and lower financial costs without affecting the normal use of raised funds [2]. Group 3: Credit Rating Adjustment - The credit rating for Sely Medical's convertible bonds has been adjusted from "BBB-" to "BB+" with a stable outlook [3]. - The previous rating was established on February 18, 2025, and the new rating was issued following a tracking analysis by Zhongceng Pengyuan Credit Rating Co., Ltd. [3]. - The adjusted rating means that the "Sely Convertible Bonds" can no longer be used as collateral for repurchase transactions [3].

Meeting Details - The third meeting of the Supervisory Board of Zhejiang Pava New Energy Co., Ltd. was held on June 27, 2025, via communication voting, with all three supervisors present [1]. - The meeting was chaired by the Chairman of the Supervisory Board, Chen Huaiyi, and complied with relevant laws, regulations, and the company's articles of association [1]. Resolutions Passed - The Supervisory Board approved the proposal to temporarily use part of the idle raised funds to supplement working capital, which is expected to improve the efficiency of fund utilization [1][3]. - The approved amount for temporary use is up to RMB 150 million (including this amount), and the decision aligns with the regulations of the Shanghai Stock Exchange and the company's fund management system [3]. - The voting results were unanimous, with 3 votes in favor, 0 against, and 0 abstentions [3].

Group 1 - The third supervisory board meeting of Hainan Huluwa Pharmaceutical Group Co., Ltd. was held on June 27, 2025, in accordance with relevant laws and regulations [1][2] - The meeting was attended by all three supervisors, and the chairman of the supervisory board presided over the meeting [1][2] - The supervisory board approved the proposal to temporarily use idle raised funds to supplement the company's working capital, which aligns with regulatory requirements and does not affect the normal investment plan of the raised funds [2] Group 2 - The voting results showed unanimous support with 3 votes in favor, 0 abstentions, and 0 votes against [2] - The supervisory board believes that the temporary use of idle funds will enhance the efficiency of fund utilization and is in the best interest of all shareholders [2]

Core Points - The company plans to use part of its idle raised funds to temporarily supplement working capital, with an amount not exceeding 12 million RMB and a duration of no more than 12 months from the board's approval date [1][4]. Summary of Fundraising Situation - The company was approved to issue up to 45.38 million new shares, with an actual issuance of 41,046,070 shares at a price of 12.52 RMB per share, raising a total of approximately 513.90 million RMB, netting about 502.38 million RMB after deducting issuance costs [1][2]. - As of June 16, 2025, the actual amount used for fundraising projects was approximately 496.14 million RMB, leaving a remaining amount of approximately 26.41 million RMB [2]. Summary of Fundraising Investment Projects - The company has several projects with varying levels of investment and usage, including: - National Class I anti-cancer drug project with a committed investment of 156.10 million RMB, with 34.94 million RMB used [2]. - Raw material drug project with a committed investment of 46 million RMB, fully utilized [2]. - Automation warehouse project with a committed investment of 36.80 million RMB, with 8.12 million RMB used [2]. - The total amount for temporary working capital supplementation is set at 12 million RMB [3][4]. Approval Process for Fund Usage - The board and supervisory committee approved the plan to use idle funds on June 25, 2025, ensuring compliance with relevant regulations and that it would not affect the normal progress of fundraising investment projects [4][5]. - The supervisory committee and the sponsor institution both expressed support for the plan, confirming it aligns with regulatory requirements and does not harm shareholder interests [5].

Core Points - The company has approved the temporary use of idle raised funds for working capital on multiple occasions, totaling RMB 16,166 million [1][2][3] - The funds will be returned to the designated account ahead of schedule, with notifications sent to the sponsor and representative [3] Summary by Document Document 1 - On August 29, 2024, the company approved the use of up to RMB 23.66 million of idle raised funds for temporary working capital, with a usage period not exceeding 12 months [1] Document 2 - On September 5, 2024, the company approved the use of up to RMB 130 million of idle raised funds for temporary working capital, with a usage period not exceeding 12 months [2] Document 3 - On September 26, 2024, the company approved the use of up to RMB 8 million of idle raised funds for temporary working capital, with a usage period not exceeding 12 months [3] - As of June 20, 2025, the company has fully repaid the total of RMB 16.166 million used for temporary working capital to the designated account [3]

Summary of Key Points Core Viewpoint - The company, Greebo (Jiangsu) Co., Ltd., is utilizing part of its idle raised funds to temporarily supplement its working capital, ensuring that this does not affect the progress of its investment projects [1][6]. Fundraising Basic Situation - The company raised a total of RMB 374,950.90 million from its initial public offering, with a net amount of RMB 354,439.66 million after deducting issuance costs [1][2]. - The funds were deposited into a special account on January 31, 2023, and were verified by Ernst & Young Huaming on February 1, 2023 [2]. Investment Project Situation - The company has made adjustments to its fundraising investment plan, which includes changes in project implementation entities and locations, as well as internal investment structure [2][3]. - The total amount of adjusted investment projects is RMB 364,833.04 million, with a remaining balance of RMB 172,124.93 million as of May 31, 2025 [4]. Previous Use of Idle Funds - The company previously used RMB 120,000 million of idle funds to temporarily supplement working capital, which was fully repaid within the stipulated 12-month period [4][5]. Current Use of Idle Funds - The company plans to use up to RMB 150,000 million of idle funds for temporary working capital, with a usage period not exceeding 12 months [6][7]. - The decision to use these funds was approved by the board and the supervisory board, ensuring that it will not impact the funding needs of investment projects [7][8]. Regulatory Compliance - The company has established a special account for the temporary use of idle funds and signed a tripartite supervision agreement with the bank and the sponsor to ensure compliance with regulations [5][6].

Group 1 - The company held its 14th meeting of the second Supervisory Board on June 19, 2025, with all three supervisors present, confirming compliance with relevant laws and regulations [1][2] - The Supervisory Board approved the proposal to temporarily use part of the idle raised funds to supplement working capital, not exceeding RMB 1.5 billion, for a period of up to 12 months [1][2] - The board concluded that this use of funds would not affect the funding needs or project progress of the fundraising projects, adhering to regulatory requirements [1]